Karyopharm Therapeutics
Karyopharm Therapeutics · 25K0
Fra 1 stk.
Markedsdata leveret af TwelveData og Morningstar
INVESTER I KARYOPHARM THERAPEUTICS MED ENDAVU: Køb Karyopharm Therapeutics ($25K0) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Karyopharm Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing therapies for cancer and other serious diseases. Karyopharm Therapeutics Inc. specializes in drugs that target nuclear export pathways, including selective inhibitor of nuclear export compounds designed to inhibit exportin 1 (XPO1). Its current portfolio centers on oncology, with marketed and late-stage programs addressing blood cancers and solid tumors. The company’s products and clinical development efforts are aimed at treating patients who need options across hematology and oncology settings, and its commercial activities support the availability of approved cancer therapies in the United States. Headquartered in Newton, Massachusetts, Karyopharm Therapeutics Inc. plays a specialized role in the biopharmaceutical market by advancing targeted treatments built around a distinct molecular mechanism.
